<DOC>
	<DOCNO>NCT02513797</DOCNO>
	<brief_summary>This study prospective , multicenter , randomize ( 2:1 ) control study evaluate safety effectiveness LARIAT System percutaneously isolate ligate Left Atrial Appendage leave atrium adjunct plan pulmonary vein isolation ( PVI ) catheter ablation treatment subject symptomatic persistent longstanding persistent atrial fibrillation . This study conduct two stage : - Limited Early Stage ( Stage 1 ) : 175 subject 50 site - Pivotal Stage ( Stage 2 ) : 600 subject 50 site All patient stage include primary analysis .</brief_summary>
	<brief_title>aMAZE Study : LAA Ligation Adjunctive PVI Persistent Longstanding Persistent Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Documented diagnosis symptomatic persistent longstanding persistent nonvalvular atrial fibrillation Failed least one Class I III Antiarrythmic drug ( AAD ) Life expectancy ≥ 1 year ; Willing able return comply schedule followup visit test ; Willing able provide write informed consent Prior procedure involve open pericardium enter pericardial space ( e.g. , coronary artery bypass graft , heart transplantation , valve surgery ) adhesion suspect ; Prior epicardial endocardial atrial fibrillation ablation procedure ; LA diameter &gt; 6 cm measure computerized tomography ; Documented embolic stroke , transient ischemic attach suspect neurologic event within 3 month prior plan intervention ; Currently exhibit New York Heart Association Class IV heart failure symptom ; Documented history right heart failure specifically right ventricle exceeds leave ventricular size ; Documented history myocardial infarction ( MI ) within 3 month prior plan study intervention ; Documented history unstable angina within 3 month prior plan study intervention ; Documented symptomatic carotid disease , define &gt; 70 % stenosis &gt; 50 % stenosis symptom ; End Stage Renal Disease ( ESRD ) document history renal replacement / dialysis ; Current document history clinically significant liver disease predisposes subject significant bleeding risk ( clinically define treat physician ) ; Any history thoracic radiation exception localize radiation treatment breast cancer ; Current document use longterm treatment corticoid steroid , include use inhale steroid respiratory disease ; Active pericarditis ; Active endocarditis ; Any documented history autoimmune disease associate pericarditis ; Evidence Pectus Excavatum ( document clinically define treat physician ) ; Untreated severe scoliosis ( document clinically define treat physician ) ; Documented Left Ventricular Ejection Fraction ( LVEF ) &lt; 30 % within 30 day prior plan intervention ; Documented presence implant congenital defect closure device , ( e.g. , atrial septal defect , patent foramen ovale ventricular septal defect device ) ; Previously attempt occlusion leave atrial appendage ( surgical percutaneous method ) ; Body Mass Index ( BMI ) &gt; 40 ; Evidence active Graves disease ; Additional Based Screening / Preprocedure Imaging Subjects also exclude meet following : Based screening compute tomography angiography perform within 90 day prior study intervention confirm core lab : Left atrial appendage morphology : Superiorposterior orient leave atrial appendage ( i.e . superior C shape ) , : 1 . Left atrial appendage LARIATapproach width ≥ 40 mm ; 2 . Left atrial appendage distal apex extend posterior ostium appendage . Left atrial appendage position behind pulmonary artery ; All leave atrial morphology : Left atrial appendage LARIAT approach width &gt; 45 mm . Based periprocedural imaging ( transesophageal echocardiography ) time LARIAT catheter ablation ) confirm institution 's designate LARIAT echocardiographer : Intracardiac thrombus ; Significant mitral valve stenosis ( i.e. , mitral valve stenosis &lt; 1.5cm2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>